Lakshmi Suryakala Gudipati

Motilal Oswal Discover- Laurus Labs venture into new disruptive therapy. Watch video- https://youtu.be/dDa1zyUVMag#LaurusLabs #stockmarket #motilaloswal #research #recommendations #LaurusLabs #stockmarket #motilaloswal #research #recommendations

https://youtu.be/TocatocO26oMotilal Oswal Discover: Bharati Airtel- Growth steady & gaining market share. #airtel #stockmarket #motilaloswal #research #recommendations #airtel #stockmarket #motilaloswal #research #recommendations

MOFSL view- Valuing at an early stage businesses on plain vanilla financial matrix might not give the right picture and may look distorted. Investors with high risk appetite can Subscribe for Listing Gains given fancy for unique and first of its kind listing in the food delivery business. Know more link - http://ow.ly/Qa2V50FvHQS#MOMarketUpdates #ZomatoIPO #IPO #IndianStockMarket #investing #recommendation #Nifty #sensex #MOMarketUpdates #ZomatoIPO #IPO #IndianStockMarket #investing #recommendation #Nifty #sensex

MOFSL Research team recommends subscribe for Indian Pesticides #IPO given the company’s presence in fast growing agrochemical space, diversified product portfolio and robust financials. Read more - http://ow.ly/TLrm50Fgt7B. . . #Subscribe #research #recommendation #MOMarketUpdates #MotilalOswal #fundamental #stock #investing #Investingtips #stockinvesting #IndianStockMarket #nifty #sensex #IPO #IPO #Subscribe #research #recommendation #MOMarketUpdates #MotilalOswal #fundamental #stock #investing #Investingtips #stockinvesting #IndianStockMarket #nifty #sensex

The Pharma stocks are positive due to multiple approvals of US FDA for different medicines. The companies are also manufacturing the drugs for the primary treatment of Covid-19. Dr Reddy's Laboratories reclaimed the tag of being the second most valuable listed pharmaceutical company. Sun Pharma is the most valued listed company of India with the market cap of Rs 1.26lakh cr. With a favourable ruling in the appeals court, the odds of launching gVascepa also rise considerably. Bristol Myers Squibb had inked a patent settlement with Dr. Reddy’s Laboratories, allowing the Indian generics company to start with a “volume-limited” launch sometime after March 2022. The exact date of the rollout, and amount of generic Revlimid Dr. Reddy’s will be allowed to sell, are confidential. But on January 31, 2026, the company will have a license to sell its generic Revlimid with no limits. #MOMarketUpdates #IndianStockMarket #MotilalOswal #NiftyPharma #NSE #BSE #Recommendation #Stocktip #Stockrecommendation

#ResultUpdate: TATA POWER: Hit by higher cost at coal JVs and Mundra; HPC recommendations can provide relief. Read the full 3QFY19 result report here: http://ow.ly/kAKa30nuo8A #ResultUpdate